Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.
作者： Zhijian Xiao , Yushu Hao , Bingcheng Liu , Lingsheng Qian
DOI: 10.1080/1042819021000006295
关键词:
摘要: The aim of this review is to summarize our experience and the current knowledge on clinical results Indirubin, a minor active constituent well-know traditional Chinese prescription, Ganggui Luhui Wan, its analogue, Meisoindigo, in treatment chronic myelogenous leukemia (CML) China. Indirubin meisoindigo induced hematologic remission patients with phase (CP) CML as effective hydroxyurea busulfan, addition, there were no significant differences median duration CP, survival blast crisis at 60 months from diagnosis indirubin, meisoindigo, busulfan treated groups. However, when was combined hydroxyurea, evidence significantly prolonged reduced incidence compared alone. critical mechanisms indirubin action have not yet been identified. Both antiproliferative apoptosis described. Further research, especially randomized trials, are required confirm role CML.
sci-hub.se 
researchgate.net 参考文章(12)
Ralph Hoessel, Sophie Leclerc, Jane A. Endicott, Martin E. M. Nobel, Alison Lawrie, Paul Tunnah, Maryse Leost, Eve Damiens, Dominique Marie, Doris Marko, Ellen Niederberger, Weici Tang, Gerhard Eisenbrand, Laurent Meijer, Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nature Cell Biology. ,vol. 1, pp. 60- 67 ,(1999) , 10.1038/9035
John M. Goldman, Brian J. Druker, Chronic myeloid leukemia: current treatment options Blood. ,vol. 98, pp. 2039- 2042 ,(2001) , 10.1182/BLOOD.V98.7.2039
Zhijian Xiao, Linsheng Qian, Bingcheng Liu, Yushu Hao, Meisoindigo for the treatment of chronic myelogenous leukaemia. British Journal of Haematology. ,vol. 111, pp. 711- 712 ,(2000) , 10.1046/J.1365-2141.2000.02357.X
Huang L, Fang Z, Wu Km, Zhang My, [Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin]. Acta pharmaceutica Sinica. ,vol. 20, pp. 821- 826 ,(1985)
R H Chen, X J Ji, L G Wang, K Li, X M Liu, Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomedical and Environmental Sciences. ,vol. 4, pp. 332- 337 ,(1991)
Ji Xj, Zhang Fr, [Studies on antineoplastic action of indirubin derivatives and analogs and their structure-activity relationships]. Acta pharmaceutica Sinica. ,vol. 20, pp. 137- 139 ,(1985)
Zhang Fr, Lei Jl, Ji Xj, Xu Yt, [Studies on the antineoplastic action and toxicity of synthetic indirubin (author's transl)]. Acta pharmaceutica Sinica. ,vol. 16, pp. 146- 148 ,(1981)
Zhang L, Wu Gy, Gao Bh, Qiu Cc, Effect of indirubin on DNA synthesis in vitro Acta Academiae Medicinae Sinicae. ,vol. 7, pp. 112- ,(1985)
Fang Fd, Wu Gy, [Studies on the mechanism of indirubin action in the treatment of chronic granulocytic leukemia. II. Effects of indirubin on nucleic acid and protein synthesis in animal transplantable tumor cells and normal proliferating cells in vitro (author's transl)]. Acta Academiae Medicinae Sinicae. ,vol. 2, pp. 83- 87 ,(1980)
YC You, JX Mi, JH Wan, TY Yang, ZC Wang, LS Qian, [Indirubin in the treatment of chronic myelocytic leukemia (CML)--estimation of labelling index of bone marrow cells by 3H-TdR]. Chinese journal of oncology. ,vol. 9, pp. 418- 420 ,(1987)